The rising prevalence in GLP-1 agonists for diabetes has led to a question about delivery routes : skin-applied devices versus pills . Usually , GLP-1 treatments were solely available in tablet form, but the emergence of skin applications presents a different way. Skin applications might suit individuals facing challenges with tablets , those wa… Read More